Aphria (NYSE: APHA) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Aphria to related businesses based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation.
This table compares Aphria and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
9.6% of Aphria shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent recommendations for Aphria and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aphria currently has a consensus target price of $9.47, suggesting a potential upside of 48.45%. As a group, “Medicinals & botanicals” companies have a potential upside of 82.65%. Given Aphria’s rivals higher probable upside, analysts plainly believe Aphria has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares Aphria and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aphria||$179.29 million||-$12.48 million||-58.00|
|Aphria Competitors||$218.50 million||-$99.79 million||-1.85|
Aphria’s rivals have higher revenue, but lower earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Aphria has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Aphria’s rivals have a beta of 2.56, suggesting that their average stock price is 156% more volatile than the S&P 500.
Aphria beats its rivals on 7 of the 13 factors compared.
Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.